ENTRY       D03455                      Drug
NAME        Cetuximab (USAN/INN);
            Cetuximab (genetical recombination) (JAN);
            Erbitux (TN)
PRODUCT     ERBITUX (ImClone LLC)
SEQUENCE    (Heavy chain)
            QVQLKQSGPG LVQPSQSLSI TCTVSGFSLT NYGVHWVRQS PGKGLEWLGV IWSGGNTDYN
            TPFTSRLSIN KDNSKSQVFF KMNSLQSNDT AIYYCARALT YYDYEFAYWG QGTLVTVSAA
            STKGPSVFPL APSSKSTSGG TAALGCLVKDYFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (Light chain)
            DILLTQSPVI LSVSPGERVS FSCRASQSIG TNIHWYQQRT NGSPRLLIKY ASESISGIPS
            RFSGSGSGTD FTLSINSVES EDIADYYCQQ NNNWPTTFGA GTKLELKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H95, H146-H202, H222-L214, H228-H'228, H231-H'231, H263-H323, H369-H427, H'22-H'95, H'146-H'202, H'222-L'214, H'263-H'323, H'369-H'427, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03162  EGFR inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FE01
            Product: D03455<JP/US>
EFFICACY    Antineoplastic, Anti-epidermal growth factor receptor antibody
  DISEASE   Squamous cell carcinoma of the head and neck [DS:H02420]
            Colorectal cancer (K-Ras wild type, EGFR-expressing) [DS:H00020]
            Colorectal cancer (BRAF mutation positive) [DS:H00020]
  TYPE      Monoclonal antibody
TARGET      EGFR [HSA:1956] [KO:K04361]
  PATHWAY   hsa04010(1956)  MAPK signaling pathway
            hsa04012(1956)  ErbB signaling pathway
            hsa05200(1956)  Pathways in cancer
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
                 L01FE01 Cetuximab
                  D03455  Cetuximab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Cetuximab
                D03455  Cetuximab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D03455  Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03162  EGFR inhibitor
                 D03455  Cetuximab
            Drug classes [BR:br08332]
             Antineoplastic
              DG03162  EGFR inhibitor
               D03455  Cetuximab
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                EGFR
                 D03455  Cetuximab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03455
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03455
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03455
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03455
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D03455
DBLINKS     CAS: 205923-56-4
            PubChem: 17397595
            NIKKAJI: J2.240.829A
///
